Invention Grant
- Patent Title: Anti-human LAG-3 antibodies and their use in immunohistochemistry (IHC)
-
Application No.: US17331344Application Date: 2021-05-26
-
Publication No.: US11667711B2Publication Date: 2023-06-06
- Inventor: Morten Draeby Sorensen , Tine Hagedorn-Olsen
- Applicant: Agilent Technologies, Inc.
- Applicant Address: US CA Santa Clara
- Assignee: AGILENT TECHNOLOGIES, INC.
- Current Assignee: AGILENT TECHNOLOGIES, INC.
- Current Assignee Address: US CA Santa Clara
- Agency: ArentFox Schiff LLP
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/28 ; G01N33/574

Abstract:
Provided are chimeric or recombinant antibodies (Ab), or antigen binding fragments thereof, or monomeric or dimeric antigen binding proteins, that can specifically bind to human LAG-3 polypeptides, including human LAG-3 polypeptides expressed on the surface of lymphocytes such as activated T cells that have infiltrated tumors or tumor infiltrating lymphocytes (TILs), and methods for making and using them. In alternative embodiments, chimeric or a recombinant antibodies (Ab), or antigen binding fragments thereof, or monomeric or dimeric antigen binding proteins as provided herein are used for in vitro diagnostics, for example, in immuno-histochemistry (IHC), for example, to diagnose and/or treat a cancer, for example, bladder cancer, urothelial carcinoma, breast cancer, lung cancer, Non-Small Cell Lung Cancer, renal carcinoma, Renal Clear cell Carcinoma and/or melanoma or malignant melanoma, by their ability to specifically bind to activated T cells that have infiltrated tumors, or tumor infiltrating lymphocytes.
Public/Granted literature
- US20210371520A1 ANTI-HUMAN LAG-3 ANTIBODIES AND THEIR USE IN IMMUNOHISTOCHEMISTRY (IHC) Public/Granted day:2021-12-02
Information query